-
MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors
•
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its Category 1 innovative drug candidate CMAB017 in advanced solid tumors. The trial will include patients with colorectal cancer, head and…
-
Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment
•
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose of RMB 402 million (USD 60 million) into its subsidiary NovoCodex Biopharmaceuticals Ltd, amounting to a combined 12.94% stake in the firm. Milestones AchievedSince the closure of its Series A financing round, NovoCodex has achieved…
-
Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion
•
China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD 322 million) through a private placement. The proceeds will be used for the Shanghai biomedicine research and development (R&D) innovation industry base program, drug discovery and pharmaceutical research and filing platform laboratory expansion program, and…
-
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval from the National Medical Products Administration (NMPA) for its generic version of Pfizer’s Ibrance (palbociclib). The drug can now be used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced…
-
Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss
•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the year ended March 31, 2022), with revenues reaching RMB 20.57 billion (USD 3 billion), up 32.6% year-on-year (YOY). The growth was driven by the pharmaceutical self-operation business and medical and digital service business. However, the…
-
Wuxi Biologics Set to Be Removed from US Restricted Trade List
•
Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US Department of Commerce restricted trade list, a development first reported in February this year. This news has significantly boosted the firm’s valuation, wiping away HKD 77 billion (USD 9.9 billion) in losses. Chinese authorities permitted…
-
CDE Releases 60th Batch of Chemical Generic Reference Preparations
•
The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference preparations, adding 93 new specifications. The public feedback deadline for this batch is July 18, 2022. Batch DetailsIn this batch, 49 specifications had their information updated. However, 16 specifications failed the review process due to…
-
Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies
•
China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD 20.9 million) in an angel financing round. The round was led by Emerging Technology Partners (ETP) and Redhill Capital, with contributions from CASI Pharmaceuticals Inc. (NASDAQ: CASI). The proceeds will be used for a clinical…
